Serina Therapeutics Announces Premium Private Placement Financing

Serina Therapeutics ( (SER) ) has provided an update.

On March 17, 2026, Serina Therapeutics entered into a securities purchase agreement for a private placement of common stock, pre-funded warrants and redeemable warrants led by board director Greg Bailey, with an initial $15 million tranche that investors funded in full by March 20, 2026 and a second tranche of up to $15 million expected by April 30, 2026. The equity is priced at $2.25 per share, a 68% premium to Serina’s March 17 closing price, and includes 50% warrant coverage at $5 per share that could add up to $33.3 million if fully exercised, while an amended September 2025 convertible note removes obligations for further borrowing.

Proceeds are earmarked to support Serina’s ongoing Phase 1b single-ascending-dose registrational study of SER-252 for advanced Parkinson’s disease, conducted under a 505(b)(2) NDA pathway with sites in Australia and the United States and topline SAD data targeted for the first half of 2027. The deal structure ties warrant callability to both share-price performance and dosing milestones in Cohort 2, aligning capital access with clinical progress, and the company has committed to register the resale of private placement shares after at least $20 million of securities have been sold.

Governance changes accompany the financing, with Bailey appointed Co-Chairman of the Board alongside existing Executive Chairman Simba Gill effective upon the initial closing, reflecting the influence of lead investor Juvenescence, the company’s largest shareholder that designated Bailey as a director. A special committee of independent directors approved the transaction on March 13, 2026 in light of related-party considerations, and investors will gain the right to designate an additional non-executive director once specified funding thresholds are met, potentially reshaping board dynamics as Serina advances SER-252 and its broader POZ-based pipeline.

The most recent analyst rating on (SER) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on Serina Therapeutics stock, see the SER Stock Forecast page.

Spark’s Take on SER Stock

According to Spark, TipRanks’ AI Analyst, SER is a Neutral.

The score is weighed down primarily by weak financial performance (large ongoing losses and significant cash burn with limited equity cushion), compounded by a negative listing-compliance event that raises uncertainty. Technicals provide a partial offset due to improving short-term momentum, but valuation is constrained by negative earnings and no dividend support.

To see Spark’s full report on SER stock, click here.

More about Serina Therapeutics

Serina Therapeutics is a clinical-stage biotechnology company developing a pipeline of wholly owned drug candidates for neurological diseases and other indications, built around its proprietary POZ Platform drug optimization technology. Headquartered in Huntsville, Alabama at the HudsonAlpha Institute of Biotechnology, the company focuses on reformulating well-known therapeutics to improve safety, pharmacokinetics and dosing via subcutaneous delivery, and it also licenses its POZ polymer for use in lipid nanoparticle drug delivery, including under a non-exclusive agreement with Pfizer.

Serina’s POZ technology is based on a synthetic, water-soluble poly(2-oxazoline) polymer engineered to offer precise control over drug loading and release rates, with the aim of maintaining more stable blood levels for drugs with narrow therapeutic windows. Its lead candidate, SER-252, is a POZ-apomorphine therapy designed to address advanced Parkinson’s disease in patients inadequately controlled by current standard-of-care treatments, positioning the company within the neurology-focused segment of the biotech market.

Average Trading Volume: 4,390,336

Technical Sentiment Signal: Sell

Current Market Cap: $27.4M

See more insights into SER stock on TipRanks’ Stock Analysis page.